CNX Therapeutics expands CNS portfolio

2 April 2024

UK-based specialty CNS-focused pharma company CNX Therapeutics today announce that it has successfully completed the acquisition of two CNS products from the French sales subsidiary of Japan’s Eisai (TYO: 4523).

CNX Therapeutics has acquired two medicines; Loxapac (loxapine) and Parkinane LP (trihexyphenidyl chloride) which are used to treat psychological disorders and Parkinson’s disease respectively. More specifically:

Loxapac, used in adults and children over 15 for the treatment of acute and chronic psychotic states and states of agitation, aggressiveness and anxiety associated with psychotic disorders of certain short-term personality disorders. The drug is available in France and Algeria.
Parkinane LP, used for the treatment of Parkinson’s disease and neuroleptic-induced parkinsonian syndrome, and also available in France and Algeria.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK